No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
XCUR Exicure
- 0.3225
- -0.0077-2.33%
Trading Jun 17 15:12 ET
2.79MMarket Cap-152P/E (TTM)
0.3499High0.3150Low68.92KVolume0.3415Open0.3302Pre Close22.99KTurnover0.88%Turnover RatioLossP/E (Static)8.65MShares1.500052wk High0.92P/B2.52MFloat Cap0.300052wk Low--Dividend TTM7.81MShs Float115.2000Historical High--Div YieldTTM10.57%Amplitude0.3000Historical Low0.3330Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Exicure Shares Are Trading Lower After the Company Reported FY23 Results and Said It Believes That Its Cash and Cash Equivalents Are Insufficient to Continue to Fund Operations and Additional Funding Is Needed in the Very Near Term
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersVenus Concept (NASDAQ:VERO) shares increased by 135.2% to $1.38 during Friday's pre-market session. The market value of their outstanding shares is at $8.7 million. Adlai Nortye (NASDAQ:ANL) sh
Exicure | 10-K: Annual report
Exicure GAAP EPS of -$2.11
Express News | Exicure Says "The Company Believes That Its Cash and Cash Equivalents Are Insufficient to Continue to Fund Operations and Additional Funding Is Needed in the Very Near Term."
Exicure FY23 Loss $16.9M >XCUR
Exicure FY23 Loss $16.9M >XCUR
Comments
$Exicure(XCUR.US$ Exicure Shares Are Trading Lower After the Company Reported FY23 Results and Said It Believes That Its Cash and Cash Equivalents Are Insufficient to Continue to Fund Operations and Additional Funding Is Needed in the Very Near Term
1
$Exicure(XCUR.US$ small float👀
2
1
$Exicure(XCUR.US$ Will go higher
$Exicure(XCUR.US$ EXICURE XCUR PATENT AGREEMENT WITH BLUEJAY; HELIUS HSDT FDA FEEDBACK
BPC UPDATE 02/06/2024 ET
Pre-Market Updates
Exicure Inc (NASDAQ: XCUR) announced that it has licensed some of its patents to Bluejay Thearapeutics for advanced clinical development on the treatment of hepatitis. Bluejay will receive an exclusive license in the field of hepatitis to all of Exicure’s relevant patents. Bluejay paid Exicure an initial small, one-time payment after the execution of the deal.![]()
BPC UPDATE 02/06/2024 ET
Pre-Market Updates
Exicure Inc (NASDAQ: XCUR) announced that it has licensed some of its patents to Bluejay Thearapeutics for advanced clinical development on the treatment of hepatitis. Bluejay will receive an exclusive license in the field of hepatitis to all of Exicure’s relevant patents. Bluejay paid Exicure an initial small, one-time payment after the execution of the deal.
1
3
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg